On April 24, in Astana, the Ministry of Health and AstraZeneca signed the implementation plan for the pharmaceutical investment project, which involves contract manufacturing of biotechnological drugs in Kazakhstan, QazMonitor reports citing the press service of AstraZeneca.
What it means: The company plans to gradually localize its production in Kazakhstan.
We are confident that contract manufacturing will ensure the transfer of AstraZeneca’s global competencies and bring expertise in the production of modern innovative drugs to Kazakhstan.
Earlier, at the end of 2023, the Ministry of Health and AstraZeneca signed a roadmap for a project aiming to localize the production of the company’s pharmaceutical products.
About the company: AstraZeneca is a British-Swedish multinational pharmaceutical and biotechnology company. The company’s portfolio includes products for the treatment of oncology (cancer), cardiovascular diseases, gastrointestinal disorders, infectious diseases, neuroscience disorders, respiratory conditions, and inflammation. It has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine. According to the company’s annual report for 2023, the company's total revenue reached $45.8 billion.
